Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TDS, FDA, FVT

FX Solutions, SAS. [FX Shoulder, Inc.] Receives FDA 510k Clearances for Glenoid Baseplate With a Central Screw and 32mm Glenosphere and Humeral Cups


DALLAS, March 2, 2020 /PRNewswire/ -- FX received 510k clearances for their Glenoid Baseplate with a Central Screw and 32mm Glenosphere and Humeral Cups for reverse shoulder arthroplasty.

The Glenoid Baseplate includes a Central Screw that has (7) different central screw size length options ranging from 8mm to 20mm in 2mm increments. This provides an alternative to the glenoid baseplate having a central post and post extensions that FX currently has available to the US market. The addition of the glenoid baseplate with a central screw allows surgeons perioperative options to address a variety of deficiencies and can now accommodate an even larger patient population and surgeon's needs.

The 32mm Glenosphere and Humeral Cups further expand the offerings that FX has available to the US market, which includes the existing sizes of 36mm and 40mm. With the 32mm components added to the FX portfolio, surgeons may be able to address more diverse patient needs.

"These are significant achievements and additions for our portfolio. There is a constant need and request for exactly these types of implants. They complement what we already have and, even more so, allows us to further compete in an extremely competitive market," said Baptiste Martin, CEO of FX Shoulder USA. "These additions continue our adventure..." he continued to say.

To see the entire FX portfolio, please visit our exhibit booth at AAOS in Orlando from March 25-27, 2020.

FX Shoulder USA, Inc. is based in Dallas, TX and is the direct provider of FX Solutions shoulder replacement devices in the U.S. FX Shoulder USA, Inc., founded in January 2018, focuses exclusively on shoulder arthroplasty. For additional information, please visit www.fxshoulder.com.

For more information contact: 
FX Shoulder USA, Inc.
Phone: 1-800-280-0775
Fax: 1-800-429-8965
[email protected]

SOURCE FX Solutions


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: